|
| |
myfortic Pages on BioPortfolio:
BioPortfolio - myfortic
FDA Investigating Potential Association between CellCept, Myfortic ... Oncology Times: ... CellCept, Myfortic Labeling Changes Reflect PML Risk 1 Jul 2008 . ...
http://www.bioportfolio.com/search/myfortic.html...
|
fda investigating potential association between cellcept, myfortic ...
oncology times:
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...
|
BioPortfolio - kidney transplant lehigh valley
Kidney Transplantation - BioPortfolio - Indepth. ... kidney transplant lehigh valley | Alefacept kidney | renal transplantation vaccination 2008 | myfortic
...
http://www.bioportfolio.com/search/_kidney_transplant___lehi...
|
BioPortfolio's Approved Drugs News by Tradename - M
MYFORTIC · MYIDYL · MYKACET · MYKINAC · MYKROX · MYLARAMINE · MYLAXEN · MYLERAN · MYLOTARG · MYMETHASONE · MYMETHAZINE FORTIS ...
http://www.bioportfolio.co.uk/approved_drugs/approved_drug_n...
|
BioPortfolio - mycophenolate sodium msds
http://www.bioportfolio.com/search/myfortic.html... BioPortfolio - impdh2 ... 287, Mycophenolic Acid, MPA, Melbex, Myfortic™, Y, Hazardous Drug List ...
http://www.bioportfolio.com/search/mycophenolate_sodium_msds...
|
BioPortfolio's Approved Drugs News by Tradename - M
MYFORTIC+MYCOPHENOLIC+ACID · MYIDYL+TRIPROLIDINE+HYDROCHLORIDE · MYKACET+ NYSTATIN+TRIAMCINOLONE+ACETONIDE · MYKINAC+NYSTATIN · MYKROX+METOLAZONE ...
http://www.bioportfolio.co.uk/approved_drugs/approved_drug_p...
|
BioPortfolio - the biotechnology, pharmaceutical, life science and ...
BioPortfolio the comprehensive website for data, information, search engine and services on biotechnology, pharmaceutical and healthcare research, ...
http://www.bioportfolio.com/...
|
BioPortfolio - Alefacept kidney
kidney transplant lehigh valley | Alefacept kidney | renal transplantation vaccination 2008 | myfortic | . Browse BioPortfolio's InDepth service . ...
http://www.bioportfolio.com/search/Alefacept_kidney.html...
|
BioPortfolio - nmo cellcept
BioPortfolio - myfortic BioPortfolio - nmo cellcept The prognosis of NMO is ... Mycophenolate (CellCept®, Myfortic®) Mycophenolate (Cellcept) is used with . ...
http://www.bioportfolio.com/search/nmo_cellcept.html...
|
Organ Transplant Immunosuppressive Markets
Myfortic Certican Simulect Financial Information F. HOFFMANN-LA ROCHE LTD History and Lines of Business Immunosuppressant Products Financial Information
...
http://www.bioportfolio.com/cgi-bin/acatalog/info_1008.html...
|
Results from other life science and pharmaceutical sites:
Document Title
receiving Myfortic should be managed in facilities equipped and staffed with ... Myfortic is available for oral use as delayed-release tablets containing ...
http://www.pharma.us.novartis.com/product/pi/pdf/myfortic.pd...
|
Communication About an Ongoing Safety Review of CellCept ...
The prescribing information for CellCept and Myfortic now includes ... Both CellCept and Myfortic are used with other drugs to suppress the immune system.
...
http://www.fda.gov/Cder/drug/early_comm/mycophenolate.htm...
|
Myfortic Linked to Pregnancy Loss, Congenital Malformations
27 Nov 2007 ... Women of childbearing age receiving mycophenolate sodium must use 2 forms of birth control.
http://www.medscape.com/viewarticle/566553...
|
IMPORTANT PRESCRIBING INFORMATION ABOUT MYFORTIC (mycophenolic ...
of the Myfortic Prescribing Information. Cases of progressive multifocal ... This new important safety information in the Myfortic Prescribing Information
...
http://www.fda.gov/medwatch/SAFETY/2008/Myfortic_DHCP_june20...
|
Sensipar, BreastScan IR, EstroGel, Myfortic Recently Approved
Approvals include an oral calcimimetic for kidney disease, a scanner for the early detection of breast cancer, transdermal hormone therapy for women, ...
http://www.medscape.com/viewarticle/471554...
|
Myfortic
Patients receiving Myfortic should be managed in facilities ... Myfortic is available for oral use as delayed-release tablets containing either 180 mg ...
http://www.fda.gov/medwatch/SAFETY/2007/Nov_PI/Myfortic_PI.p...
|
CellCept, Myfortic Labeling Changes Reflect PML Risk
1 Jul 2008 ... Healthcare providers should include progressive multifocal leukoencephalopathy in the differential diagnosis of immunosuppressed patients ...
http://www.medscape.com/viewarticle/576907...
|
New Study Reports Two Thirds of Renal Recipients Switched to ...
"This study showed that recipients switched to myfortic reported reduced symptoms." ... Conversion to myfortic benefitted both groups of recipients with
...
http://www.pharma.us.novartis.com/newsroom/press-release.jsp...
|
IMPORTANT
to MPA, the active ingredient in Myfortic, following oral or IV administration. The ... associated with the use of Myfortic to Novartis Pharmaceuticals ...
http://www.fda.gov/MedWatch/SAFETY/2007/Myfortic_DHCP_Letter...
|
Novartis Corporation Release: After Conversion To Myfortic(R), Two ...
In addition, after conversion to myfortic more than two-thirds of patients and physicians reported an overall reduction in the gastrointestinal symptom ...
http://www.biospace.com/news_story.aspx?NewsEntityId=25366...
|
|
